NEJM Journal Watch
Really Rapid Review — CROI 2017, Seattle
Paul E. Sax, MD
Paul E. Sax, MD
The Conference on Retroviruses and Opportunistic Infections (CROI) returned to Seattle this past week for its 24th meeting. It’s the 4th time CROI has been held in Seattle, an excellent city for a meeting of this size, which includes “only” 4200 people. The convention center is pleasant and user-friendly — big but not cavernous, actually encourages interactions with colleagues — and there are numerous hotels and restaurants within walking distance, plus more Starbucks per square foot than any place on the planet.
From a content perspective, the big change for CROI 2017 was the return of numerous studies on antiretroviral therapy, studies involving both approved and investigational agents. The last several years, by contrast, had relative dominance of pre-exposure prophylaxis and hepatitis C studies. With PrEP, one had the sense at the meeting that we’re now waiting for the next strategies (long-acting injectables, for example).
As for hepatitis C, well that’s been all but solved (except for the implementation part). How do you improve on 97%-plus cured. Hooray!
Links
Conference Coverage
Conference on Retroviruses and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
NATAP
hivandhepatitis.com
http://www.aidsmap.com/croi-2017
http://www.medpagetoday.com/meetingcoverage/croi
Conference on Retroviruses and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
NATAP
hivandhepatitis.com
http://www.aidsmap.com/croi-2017
http://www.medpagetoday.com/meetingcoverage/croi
No comments:
Post a Comment